Biogen’s Hemophilia B drug Gets Green Signal in Canada

Biogen’s Hemophilia B drug Gets Green Signal in Canada

The latest statement by the Biogen Idec Inc. has revealed that the long-lasting hemophilia B drug, Alprolix, has gained green signal from Canada. The company stock closed at $347.04 in the US stock market on Thursday.

The main advantage of the drug is that it is administered only once a week or once in every 10 to 14 days to protect against bleeding episodes whereas earlier treatments have to be administered two or three times a week.

The officials reported that the single injection of the drug is capable of controlling 90% of bleeding in late-stage clinical trial.

Hemophilia B is a rare inherited disorder which affects about 4,000 people in United States and about 25,000 across the world. Hemophilia A is another more common form of the disease that affects about 20,000 people in the US. Biogen and Swedish Orphan Biovitrum AB are developing the Alprolix which is expected to be approved in US in later half of the year.

Biogen is working on another mission to develop a drug, Elocate, to treat hemophilia A, disease in which patients suffer reduced levels of coagulation factor VIII. The company said that the treatments for hemophilia B generate about $1 billion per year whereas the market for hemophilia A therapies generates revenue of about $6 billion.

The Cambridge based company added that the approval of the Alprolix will generate sales of $286 million by 2019 while Elocate can generate sales over $1.1 billion.


FrenchTribune Specials

Windows 10 Anniversary Update will add two advanced security capabilities

The forthcoming Anniversary Update of Microsoft Woindows10 OS will bring along the addition of several new features, including advanced security capabilities which will enable IT managers to more effectively lock down the computers in their organization.

The two new advanced security capabilities which are being added to Windows 10 OS as...

Exxon reports 46% decline in First Quarter earning

On Thursday, Exxon reported a 46% decline in earnings in the first quarter, by earning $4.9 billion compared with $9.1 billion in the same quarter a year ago. Exxon's top and bottom lines declined due to lower oil prices.

It was the...

Most Popular

Study finds no link between IVF and risk of breast cancer

A new study claimed that women who undergo in-vitro...

Nvidia unveils its latest flagship graphics card --- Titan X

Chip maker Nvidia has unveiled its newest flagship...

Nail biting and thumb-sucking might be healthy for children

To all those parents who have tough time in making their...

Facebook Messenger app grows to more than 1 billion users

On Wednesday, social network Facebook announced that its...

Poll

Can Greece Come out of Economic Problems: